EPIC.CN 1CM Inc. (CNQ) down 28.95% Feb 17, 2026: support near C$0.13

EPIC.CN stock dropped 28.95% to C$0.135 in market hours on 17 Feb 2026 after heavy selling pushed volume to 31,000.00 shares. This move put 1CM Inc. (EPIC.CN) on today’s top losers list on the CNQ in Canada and tested intraday support at the year low of C$0.13. The decline came against a 50-day average of C$0.1764 and 200-day average of C$0.25635, signaling elevated short-term pressure even as some valuation metrics look cheap versus peers.

Price action and intraday drivers for EPIC.CN stock

EPIC.CN stock opened at C$0.155 and hit a day low at C$0.130 before settling at C$0.135. The one-day change of -28.95% followed heavier-than-normal trading, with relative volume at 3.80, well above the average volume of 8,164.00. Price weakness aligned with a break below the middle Bollinger band (C$0.18) and a MACD near zero, indicating sellers dominated for the session.

Valuation snapshot and financial ratios for EPIC.CN stock

At the close, 1CM reported EPS of 0.02 and a trailing PE shown in company data at 6.75, below the Healthcare sector average PE of 20.19, suggesting the stock trades at a steep discount on simple earnings metrics. Book value per share is 0.25 and price-to-book is 0.54, implying the market values EPIC.CN at roughly half its book value. Current ratio stands at 3.18, and debt-to-equity is 0.17, which supports liquidity despite the price drop.

Technical picture and support levels for EPIC.CN stock

Technicals point to short-term bearish momentum: RSI at 39.31, ADX 26.35 showing a strong trend, and the 50-day average (C$0.1764) above the current price. Immediate support is the year low at C$0.13 and Bollinger lower band at C$0.13. A close back above C$0.155 and the 50-day average would be required to stabilize the chart and reduce downside risk.

Sector context and what the Healthcare backdrop means for EPIC.CN stock

1CM Inc. trades in the Healthcare sector and the Drug Manufacturers – Specialty & Generic industry. The sector’s recent performance shows mixed returns and an average PE around 20.19, making EPIC.CN appear cheaper on PE and price-to-sales. However, sector headwinds and regulatory noise for cannabis-related businesses increase execution risk despite low valuation multiples.

Meyka AI rates EPIC.CN with a score out of 100 and technical summary

Meyka AI rates EPIC.CN with a score out of 100: 71.20 / 100 — Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The scoring model highlights attractive price-to-book and low market cap but flags volatility and narrow liquidity.

Key technicals: 50-day average C$0.1764, 200-day average C$0.25635, RSI 39.31, ADX 26.35. These indicators show the stock is oversold in the short term but still in a downtrend.

Meyka AI’s forecast model projects targets for EPIC.CN stock

Meyka AI’s forecast model projects a quarterly near-term target of C$0.16 and a monthly model projection of C$0.30. Against the current price of C$0.135, the implied move to C$0.16 is 18.52% upside and the move to C$0.30 is 122.22% upside. Forecasts are model-based projections and not guarantees.

Final Thoughts

EPIC.CN stock’s steep decline on 17 Feb 2026 to C$0.135 reflects a liquidity-driven sell-off that tested the year low at C$0.13. Fundamentals show low price-to-book (0.54) and strong current ratio (3.18), while the trailing PE reported is 6.75, below the sector average, which points to a valuation gap. Technicals remain weak: RSI 39.31, 50-day average C$0.1764, and ADX 26.35. Meyka AI’s forecast flags a near-term target of C$0.16 (implied 18.52% upside) and a more aggressive monthly projection of C$0.30 (implied 122.22% upside). Meyka AI rates EPIC.CN at 71.20 out of 100 (Grade B+, suggestion BUY), but warns of elevated volatility and limited average trading volume of 8,164.00 shares. Use tight risk controls and watch for a confirmed recovery above C$0.155 or improving volume as signals the downtrend may be losing momentum. For real-time updates consult the 1CM investor site and our Meyka AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.